Frühwald T, Böhmer F
Haus der Barmherzigkeit, Wien.
Wien Med Wochenschr. 1988 Mar 15;138(5):102-6.
In the present open clinical pilot study of 12 months duration we tested the metabolic and hemato-biological efficacy as well as the clinical tolerance of the oral antidiabetic agent gliclazide, a second-generation sulfonylurea derivate, on a group of 20 hospitalized geriatric patients (mean age 80.5 +/- 10.2 years). Gliclazide was proven to be a reliable blood-sugar lowering agent with a generally good subjective tolerance. There were no undesired side-effects on the renal, hepatic and hematopoietic systems.
在这项为期12个月的开放性临床试点研究中，我们对一组20名住院老年患者（平均年龄80.5±10.2岁）测试了口服抗糖尿病药物格列齐特（一种第二代磺脲类衍生物）的代谢和血液生物学疗效以及临床耐受性。格列齐特被证明是一种可靠的降血糖药物，总体主观耐受性良好。对肾、肝和造血系统没有不良副作用。
